| Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis JP Abeykoon, S Zanwar, A Dispenzieri, MA Gertz, N Leung, T Kourelis, ... Leukemia 33 (2), 531-536, 2019 | 87 | 2019 |
| Progression risk stratification of asymptomatic Waldenström macroglobulinemia M Bustoros, R Sklavenitis-Pistofidis, P Kapoor, CJ Liu, E Kastritis, ... Journal of Clinical Oncology 37 (16), 1403-1411, 2019 | 83 | 2019 |
| EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? A Joshi, S Zanwar, V Noronha, VM Patil, A Chougule, R Kumar, A Janu, ... OncoTargets and therapy, 1859-1863, 2017 | 63 | 2017 |
| Immune-based therapies in the management of multiple myeloma S Zanwar, B Nandakumar, S Kumar Blood cancer journal 10 (8), 84, 2020 | 54 | 2020 |
| Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes JP Abeykoon, S Zanwar, SM Ansell, MA Gertz, S Kumar, M Manske, ... British journal of haematology 188 (3), 394-403, 2020 | 46 | 2020 |
| Neoadjuvant chemotherapy in locally advanced and borderline resectable nonsquamous sinonasal tumors (esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation) VM Patil, A Joshi, V Noronha, V Sharma, S Zanwar, S Dhumal, S Kane, ... International Journal of Surgical Oncology 2016 (1), 6923730, 2016 | 46 | 2016 |
| Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia S Zanwar, JP Abeykoon, E Durot, R King, GE Perez Burbano, S Kumar, ... American journal of hematology 95 (3), 274-281, 2020 | 41 | 2020 |
| Antibiotic lock therapy for salvage of tunneled central venous catheters with catheter colonization and catheter‐related bloodstream infection S Zanwar, P Jain, A Gokarn, SK Devadas, S Punatar, S Khurana, A Bonda, ... Transplant Infectious Disease 21 (1), e13017, 2019 | 40 | 2019 |
| Primary systemic amyloidosis in patients with Waldenström macroglobulinemia S Zanwar, JP Abeykoon, SM Ansell, MA Gertz, A Dispenzieri, E Muchtar, ... Leukemia 33 (3), 790-794, 2019 | 38 | 2019 |
| Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia JP Abeykoon, S Zanwar, SM Ansell, J Winters, MA Gertz, RL King, ... American journal of hematology 93 (11), 1384-1393, 2018 | 28 | 2018 |
| Risk factors for severe infection and mortality in patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis M Ho, S Zanwar, FK Buadi, S Ailawadhi, J Larsen, L Bergsagel, M Binder, ... American journal of hematology 98 (1), 49-55, 2023 | 22 | 2023 |
| Outcomes after treatment with cobimetinib in patients with Rosai-Dorfman disease based on KRAS and MEK alteration status JP Abeykoon, KL Rech, JR Young, A Ravindran, GJ Ruan, S Dasari, ... JAMA oncology 8 (12), 1816-1820, 2022 | 22 | 2022 |
| Challenges and strategies in the management of multiple myeloma in the elderly population S Zanwar, JP Abeykoon, P Kapoor Current Hematologic Malignancy Reports 14, 70-82, 2019 | 22 | 2019 |
| Ixazomib: a novel drug for multiple myeloma S Zanwar, JP Abeykoon, P Kapoor Expert Review of Hematology 11 (10), 761-771, 2018 | 22 | 2018 |
| A prognostic index predicting survival in transformed Waldenström macroglobulinemia E Durot, L Kanagaratnam, S Zanwar, E Kastritis, S D’Sa, R Garcia-Sanz, ... haematologica 106 (11), 2940, 2021 | 19 | 2021 |
| Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia S Zanwar, JP Abeykoon, SM Ansell, MA Gertz, C Colby, D Larson, ... British journal of haematology 195 (2), 210-216, 2021 | 16 | 2021 |
| Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia JP Abeykoon, S Zanwar, SM Ansell, E Muchtar, R He, PT Greipp, RL King, ... American journal of hematology 96 (8), 945-953, 2021 | 16 | 2021 |
| Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality? VM Patil, V Noronha, A Joshi, S Zanwar, A Ramaswamy, S Arya, ... South Asian Journal of Cancer 5 (04), 182-185, 2016 | 15 | 2016 |
| Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma S Zanwar, M Ho, P Kapoor, A Dispenzieri, MQ Lacy, MA Gertz, FK Buadi, ... Leukemia 36 (3), 873-876, 2022 | 14 | 2022 |
| Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients S Zanwar, V Noronha, A Joshi, VM Patil, A Chougule, R Kumar, S More, ... Indian Journal of Cancer 54 (1), 280-284, 2017 | 13 | 2017 |
